Shares Magazine
0.22p+0.04 (+18.92%)25 Apr 2024, 08:10
Jump to:
Nuformix PLC Fundamentals
| Company Name | Nuformix PLC | Last Updated | 2024-04-25 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 819.309 m | Market Cap | £1.80 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | £-0.00 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.0408 | Cash Equity Ratio | 0.0849 |
| Quick Ratio | 3.4504 | Current Ratio | 3.45 |
| Price To Book Value | 0.3613 | ROCE | 0 |
Nuformix PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Nuformix PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | 0 | £438.00 | £957.00 |
| Intangible Assets | £4.08 m | £4.15 m | £4.19 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £4.08 m | £4.15 m | £4.19 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £48,938.00 | £171,659.00 | £17,518.00 |
| Cash & Equivalents | £202,548.00 | £464,095.00 | £1.67 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £4.42 m | £4.98 m | £6.01 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £222,990.00 | £237,861.00 | £324,624.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £222,990.00 | £237,861.00 | £324,624.00 |
| Net assets | £4.20 m | £4.74 m | £5.69 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £744,309.00 | £615,609.00 | £591,609.00 |
| Share Premium | £6.66 m | £6.50 m | £6.38 m |
| Profit / Loss | -£927,972.00 | -£1.27 m | -£1.38 m |
| Other Equity | £4.20 m | £4.74 m | £5.69 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £4.20 m | £4.74 m | £5.69 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.0408 | 1.0408 | 1.0408 |
| Cash / Equity | 0.0849 | 0.0849 | 0.0849 |
| EPS | £-0.00 | £-0.00 | £-0.00 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£546,232.00 | -£1.35 m | -£845,166.00 |
| Cashflow before financing | -£261,547.00 | -£1.21 m | £1.08 m |
| Increase in Cash | -£261,547.00 | -£1.21 m | £1.13 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 0 | £50,000.00 | £195,550.00 |
| Cost of sales | 0 | £1,695.00 | £62,307.00 |
| Gross Profit | 0 | £48,305.00 | £133,243.00 |
| Operating Profit | -£927,972.00 | -£1.27 m | -£1.37 m |
| Pre-Tax profit | -£927,972.00 | -£1.27 m | -£1.38 m |
Nuformix PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK. |
| Latest Interim Date | 30 Jun 2023 |
| Latest Fiscal Year End Date | 3 Jan 2024 |
Nuformix PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2018-08-17 | Mr. Anthony Henry Reeves | Non-Executive Director |
| 2022-05-31 | Dr. Alastair James Riddell | Executive Director,Chairman |
| 2021-05-24 | Dr. Karl Keegan | Non-Executive Director |
| 2020-01-31 | Professor Francis John Lidgey | Non-Executive Director |
| 2018-08-17 | Mr. Pascal Hughes | Executive Director,Chief Executive Officer |
| 2020-02-05 | Mr. David Joszef Tapolczay | Non-Executive Director,Chairman |
| 2024-01-15 | Dr. Daniel John Gooding | Executive Director |
| 2019-09-10 | Mr. Kirk Siderman-Wolter | Non-Executive Director |
| 2022-08-01 | Dr. Joanne Holland | Executive Director,Chief Scientific Officer |
| 2024-01-15 | Mrs. Madeleine Elizabeth Kennedy | Non-Executive Director |
| 2024-01-15 | Dr. Julian Gilbert | Non-Executive Director,Chairman |
| 2021-11-09 | Dr. Anne Brindley | Executive Director,Chief Executive Officer |
Nuformix PLC Contact Details
| Company Name | Nuformix PLC |
|---|---|
| Address | 60 Gracechurch Street, 6th Floor, London, EC3V 0HR |
| Telephone | +44 1223627222 |
| Website | https://www.nuformix.com |
Nuformix PLC Advisors
| Stockbroker | Whitman Howard |
|---|---|
| Phone | +44 2076591234 |
| Solicitor | Shakespeare Martineau LLP |
|---|---|
| Phone | +44 1908304443 |
| Auditor | Moore Stephens LLP |
|---|---|
| Phone | +44 2073349191 |
| Fax | +44 2072483408 |
| Bank | HSBC Bank PLC |
|---|
| Financial PR Adviser | Gable Communications |
|---|---|
| Phone | +44 2071937463 |
| Financial Adviser | EGR Broking Limited |
|---|---|
| Phone | +44 2036979495 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Stockbroker | EGR Broking Limited |
|---|---|
| Phone | +44 2036979495 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Anglo American PLC | 2,490.50 | 12.95 |
| Inchcape PLC | 778.24 | 8.24 |
| Astrazeneca PLC | 12,060.00 | 6.24 |
| Unilever PLC | 4,075.00 | 5.49 |
| Barclays PLC | 200.78 | 5.04 |
| Wizz Air Holdings PLC | 2,214.00 | 4.73 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Moonpig Group PLC | 157.40 | -11.37 |
| Trainline PLC | 310.82 | -9.38 |
| Wh Smith PLC | 1,182.00 | -6.04 |
| Bakkavor Group PLC | 116.00 | -5.69 |
| Legal & General Group PLC | 235.70 | -5.19 |
| Bae Systems PLC | 1,313.00 | -3.70 |